Death rates are declining for many common cancers in the U.S., report finds
Death rates are declining for more than half of the most common forms of cancer…
Category: Biotech
Opinion: Uterine fibroids affect millions of women. Why has this condition been overlooked for decades?
In 2007, the late Rep. Stephanie Tubbs Jones (D-Ohio) wrote an op-ed calling for passage…
STAT+: Sonde’s voice health tracking comes to Qualcomm’s smartphone chips
Vocal biomarker startup Sonde has been quietly plotting a way to make tracking respiratory and…
Can we stretch existing Covid vaccines to inoculate more people? Experts are divided
With the global supply of Covid-19 vaccine still woefully inadequate, vaccine makers are scouring the…
STAT+: Pharmalittle: Another lawmaker calls for probe of FDA approval of Alzheimer’s drug; Roche urged to lower price of Covid-19 therapy
Top of the morning to you. Another busy day is unfolding here on the Pharmalot…
Opinion: Listen: A biostatistician on the ‘gold mine’ in our sewers
What if every time we went to the bathroom, we could say we contributed to…
Opinion: Aduhelm’s accelerated approval offers a promising roadmap for rare neurological diseases
The FDA’s decision to grant accelerated approval to Biogen’s aducanumab (Aduhelm) for the treatment of…
How Doximity parlayed its popularity with doctors into a blockbuster IPO
Doximity exploded onto the public markets last month with an IPO that saw share values…
Organ donations held almost steady during the pandemic, as the U.S. transplant system scrambled to keep going
This is not a pandemic “silver lining” story. This is a could-have-been-far-worse story about how…
STAT+: Doctors Without Borders urges Roche to cut price of drug now recommended for Covid-19
After the World Health Organization recommended a Roche (RHHBY) drug to treat severe Covid-19, Doctors…
Smokers of menthol cigarettes have a harder time quitting, large new study finds
A new study published Tuesday finds that smoking menthol cigarettes versus unflavored cigarettes is associated…
Are pharma mergers bad for biotech?
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
Apple’s fall risk feature, 2021 in deals, & the fax facts
You’re reading the web edition of Health Tech, STAT’s twice-weekly newsletter about how tech is…
STAT+: The failure of a cancer drug study leaves Cel-Sci on the brink of collapse
The failure of Cel-Sci’s immunotherapy treatment called Multikine to prolong the survival of patients with…
Opinion: Why aren’t diseases like HIV and malaria, which still kill millions of people a year, called pandemics?
The furor about vaccine nationalism and sharing doses of Covid-19 overshadows a fundamental issue: What…
STAT+: Pharmalittle: Purdue wants to shower employees with $34.7 million in bonuses; Emergent faces shareholder suits
Good morning, everyone, and welcome to another working week, albeit an abbreviated one on this…
STAT+: If Apple takes aim at fall-prevention, will the rest of the health system hear it?
Using troves of data from iPhone users, Apple thinks it’s cracked an elusive problem: Identifying…
Opinion: Patient advocacy groups and innovators must partner to advance new treatments
People living with debilitating conditions and life-threatening diseases are often put in the terrible position…
STAT+: The most intriguing health tech deals of the year (so far)
In the world of digital health, money is flying around like never before. All that…
STAT+: Is the Alzheimer’s Association really pushing Biogen to lower its new drug’s price — or is it lip service?
WASHINGTON — The Alzheimer’s Association stunned Washington last month when it urged Biogen to lower…
The 36 best books and podcasts on health and science to check out this summer
In this time of transition, we’re back with our annual list of health, medicine, and…
For people in sickle cell crisis, specialized infusion centers offer far better care than the ER, study finds
People with sickle cell disease who were experiencing acute pain crises received far better care…
STAT+: Regulators in many European countries fail to ensure clinical trial data are available
Amid ongoing concerns over clinical trial transparency, a new report finds “notable gaps” in the…
STAT+: Purdue wants to shower employees with nearly $35 million in different kinds of bonuses
As Purdue Pharma attempts to win a controversial reorganization plan in bankruptcy court, the drug…
STAT+: Supreme Court to take up hospitals’ challenge to Medicare drug pay cuts
WASHINGTON — In a win for safety-net hospitals, the Supreme Court decided to hear their…
STAT+: Pharmalittle: Glaxo rejects hedge fund’s demands; FTC approves resolutions to probe pharma repeat offenders
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Regeneron’s George Yancopoulos talks CRISPR, obesity drugs, and the next generation of Covid antibody cocktails
The discovery of a rare genetic mutation that seems to protect certain people from becoming…
Opinion: Outdated Medicare rules threaten older Americans’ access to home medical equipment
Pandemic-related breaks in global supply chains for drugs and essential medical supplies are affecting the…
Opinion: The health care workforce is understaffed for life after Covid-19
As the U.S. gradually unburies itself from the Covid-19 pandemic, some people have been sounding…
Scientists devise a battery-free pacemaker that can be absorbed by the body
Scientists have designed a temporary, battery-free pacemaker that can be broken down by the patient’s…
STAT+: Inside the ‘land grab’ for virtual-first care: how an unprecedented flurry of deals is shaping the new digital health landscape
Teladoc’s blockbuster merger with Livongo in 2020 would’ve been unthinkable just a few years ago….
Listen: A CRISPR milestone, Biogen’s FDA saga, & George Yancopoulos on biotech in 2021
How much can CRISPR really do? Has the FDA been totally honest? And is it…
STAT+: U.S. cancer drug prices were higher at launch than in three European countries — and just kept climbing
In the latest bid to compare drug costs, a new study finds that prices for…
Researchers raise concerns about using genetic risk scores to pick ‘healthier’ embryos
As more people turn to in vitro fertilization for help with conceiving, a host of…
STAT+: Nestle Health Science will split profits from Seres microbiome drug, if it’s approved
Seres Therapeutics has announced a new deal with its long-time partner, Nestle Health Science, to…
STAT+: Pharmalittle: Glaxo under more pressure from activist investor; WHO urges Gilead to lower price of black-fungus drug
Hello, everyone, and how are you today? A shiny sun and delightful breeze are enveloping…
STAT+: In a new role at health tech startup Maven, Neel Shah wants to make sure pregnant people aren’t ‘lost’
When celebrated Boston OB-GYN Neel Shah first learned of the chance to help build a…
Could editing the genomes of bats prevent future coronavirus pandemics? Two scientists think it’s worth a try
Amid the devastating Covid-19 pandemic, two researchers are proposing a drastic way to stop future…
Opinion: Something to celebrate: delivering vaccines to essential workers
Covid-19 vaccines are cause for celebration. Family members are reuniting, people are traveling and returning…
STAT+: The biotech scorecard for the third quarter: 12 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third…
STAT+: Washington’s antitrust push could limit Amazon, Google’s health care ambitions
WASHINGTON — Washington is abuzz with an ambitious new antitrust effort to rein in the…
Calls grow for an investigation into FDA approval of Biogen’s Alzheimer’s drug
WASHINGTON — Former health secretary Donna Shalala called for a federal investigation into the Food…
STAT+: Mallinckrodt cleared to sell a rare disease drug to a startup, but parents worried over ongoing access
A federal bankruptcy court judge has approved the sale of a rare disease drug to…
STAT+: Gene therapy to regenerate cardiac muscle after a heart attack passes a key test in pigs
By delivering a viral payload of gene silencers directly to the heart, scientists have developed…
STAT+: Pharmalittle: Most doctors disagree with FDA approval of the Alzheimer’s drug; women underrepresented in life sciences C-suites
Good morning, everyone, and how are you today? The heat continues to rise here on…
STAT+: Revised analysis nudges up cost-effective price for Biogen’s Alzheimer’s drug to $3,000 to $8,400 a year
The controversial new Alzheimer’s drug from Biogen (BIIB) would be cost-effective only if priced between…
Opinion: Listen: A sister on watching the mental health care system fail her brother
In this week’s episode of the “First Opinion Podcast,” Lizzy Feliciano talks about her brother,…
Opinion: Copay assistance should count as part of patients’ cost sharing for medications
The Biden administration has made health equity a priority and it has been a constant…
STAT+: Poll: Most neurologists and primary care doctors disagree with FDA’s approval of Alzheimer’s drug
A majority of U.S. physicians disagree with the decision by the Food and Drug Administration…
STAT+: The health tech tracker for the third quarter: 11 pivotal industry events to watch
The third quarter will answer crucial questions about the near-term future of digital health. Will…